This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yao, X. Articles by Hoffman, A. R. Search for Related Content PubMed PubMed Citation Articles by Yao, X. Articles by Hoffman, A. R.

A Novel Orthotopic Tumor Model to Study Growth Factors and Oncogenes in Hepatocarcinogenesis¹

Medical Service, VA Palo Alto Health Care System and Division of Endocrinology, Department of Medicine, Stanford University, Palo Alto, California 94304 [X. Y., M. D., Z. Z., T. L., Y. Y., A. R. H.]; GMR Epigenetics Corporation, Sunnyvale, California 94085 [J-F. H., H. S., X. Z.]; and Department of Pharmacology, Shanghai Institute of Pharmaceutical Industry, Shanghai, People’s Republic of China [H. Y., H. L.]

An orthotopic xenograft tumor model of hepatocellular carcinoma was created by injection of Hep 3B cells directly into the liver parenchyma of nude mice. Tumors were localized primarily in the injected lobe of the liver, beginning from the third week after tumor cell implantation. Thereafter, tumors grew rapidly, and animals usually died from hepatocellular carcinoma within 2 months. Insulin-like growth factor II, an embryonic growth factor and mitogen, is overexpressed in these tumors at both mRNA and protein levels. Oncogenes, such as c-myc, c-fos, and c-jun, are also up-regulated in this model. -Fetal protein can be detected shortly after implantation and correlates with tumor growth, and measurement of serum -fetal protein serves as an early biomarker to monitor the effect of antitumor therapy. Using this model, we have shown that inhibition of insulin-like growth factor II expression by a short methylated oligonucleotide prolongs survival. This in situ tumor model thus provides a fast, reliable, and reproducible means to study the therapeutic effect of inhibitors of growth factors and oncogenes in liver cancer.

This article has been cited by other articles:

				M. Hopfner, V. Baradari, A. Huether, C. Schofl, and H. Scherubl The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer, March 1, 2006; 13(1): 135 - 149. [Abstract] [Full Text] [PDF]

				C. Han and T. Wu Cyclooxygenase-2-derived Prostaglandin E2 Promotes Human Cholangiocarcinoma Cell Growth and Invasion through EP1 Receptor-mediated Activation of the Epidermal Growth Factor Receptor and Akt J. Biol. Chem., June 24, 2005; 280(25): 24053 - 24063. [Abstract] [Full Text] [PDF]

				F. E. Domann and B. W. Futscher Flipping the Epigenetic Switch Am. J. Pathol., June 1, 2004; 164(6): 1883 - 1886. [Full Text] [PDF]